Boston Scientific bankrolls GI research; J&J launches new surgical tech;

@FierceMedDev: Gore's endovascular graft-repair device gains wider FDA nod. Item | Follow @FierceMedDev

@DamianFierce: St. Jude is riding into India with a new pacemaker and a plan to boost sales. Story | Follow @DamianFierce

@MarkHFierce: We have a new round of stories at FierceDiagnostics. Check them out | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Civitas corrals $38M for inhaled Parkinson's treatment. More from FierceDrugDelivery | Follow @MichaelGFierce

> Boston Scientific ($BSX) said it is pledging grant money over the next three years to help support gastrointestinal technology research and education. Item

> A division of the DePuy Synthes arm of Johnson & Johnson ($JNJ) is rolling out new surgical instruments that allow for less invasive surgical fixation and stabilization of rib fractures. Item

> San Diego's Aethlon Medical has launched Exosome Sciences, a subsidiary devoted to developing diagnostic technologies targeting remnants of diseased cells. Release

> Gore has enrolled its first patient in an FDA-targeted study of its carotid stent. News

> Welch Allyn inked a major product service partnership deal with Italy's TBS Group to have that company service Welch Allyn customers in the Middle East. Item

> Eso-Technologies in Wisconsin has raised a small, second Series A round to help back further development of a monitoring device designed to reduce the risk of heart attacks for people undergoing surgery. Story

> Whole-body MRI scans may work wonders in predicting cardiovascular disease in diabetics, according to a study. Article

Biotech News

@FierceBiotech: ICYMI yesterday--Industry Voices: Breakthrough designation Q&A via Michelle Rohrer. Commentary | Follow @FierceBiotech

@JohnCFierce: I think the patient perspective many news orgs have fundamentally corrupts coverage of animal studies. Article | Follow @JohnCFierce

@EmilyMFierce: Genia Technologies, Columbia, Harvard nab $5.3M NIH grant for genome sequencing. More from FierceBiotech Research | Follow @EmilyMFierce

@Ry_McBride: I'm talking to Treato (social listening for pharma) later today. Stay tuned for post at FierceBiotech IT. | Follow @Ry_McBride

> Gilead leaps ahead with FDA app for PI3K cancer killer. More

> Biotech R&D spending roars ahead as Big Pharma grimly holds the line. Article

> Sanofi cancels diabetes drug pitch--for now--as GLP-1 competition races ahead. Story

> GlaxoSmithKline's great, terrible, wonderful, not-so-good year. Article

Pharma News

@FiercePharma: China's state TV broadcasts corruption allegations against Sino Biopharm, first domestic drugmaker publicly tagged in bribery probe. | Follow @FiercePharma

@CarlyHFierce: Second recall in as many weeks for J&J--this time, a moldy schizophrenia drug is the culprit. More from FiercePharmaManufacturing | Follow @CarlyHFierce

> Bristol-Myers' Yervoy hopes snag on flubbed prostate cancer trial. Story

> China's Sino Biopharm reels after CCTV accuses unit of bribing doctors. More

> Botox approval for crow's feet provides bit of upbeat news for beleaguered Allergan. Article

Pharma Manufacturing News

@EricPFierce: South Africa's Aspen says manufacturing assets it is getting from GSK, Merck part of global push. Story | Follow @EricPFierce

> J&J recall streak continues with moldy schizophrenia drug. News

> Eisai U.K. site OK'd to make Fycompa. Report

> Merged CFR, Adcock Ingram to have 18 manufacturing sites. Article

> KKR deal in Gland Pharma calls for $100M plant investment. Item

> Pharma packaging growing market with openings for good ideas. More

Vaccines News

> Meningitis cases fall 94% following vaccine introduction. Report

> Low uptake of Merck's Zostavax costing healthcare systems. Item

> Early-phase HIV vaccines advance on positive data. News

> Implant aims to end logistical challenges of cancer vaccines. More

> Pfizer details plans to expand vaccine portfolio beyond Prevnar. Article

> PhIII data dents GSK's hopes for cancer vaccine. Story

Suggested Articles

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions.

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.